Meduloc raises $4M Series B to launch its nitinol fracture fixation platform
What's the deal? MedulocDealroom has a profile for this one. Try Dealroom →, a West Chester, Pennsylvania orthopedic device company, has closed a $4 million Series B round led by GenHenn CapitalDealroom has a profile for this one. Try Dealroom →. Participants included Life Sciences Greenhouse InvestmentsDealroom has a profile for this one. Try Dealroom →, Ben Franklin Technology Partners of Southeastern PennsylvaniaDealroom has a profile for this one. Try Dealroom →, Broad Street AngelsDealroom has a profile for this one. Try Dealroom →, and former Los Angeles DodgersDealroom has a profile for this one. Try Dealroom → player Andre Ethier, alongside existing and new investors.
What's the endgame? Meduloc sells an FDA-cleared, single-use system that uses a flexible nitinol intramedullary implant to stabilise fractures. The company says it preserves anatomy and avoids joint violation in certain uses across upper- and lower-extremity long-bone fractures in adult and pediatric patients.
Why now? The financing marks Meduloc's shift from development into commercialisation. It funds a controlled alpha launch, further clinical evidence, and the commercial infrastructure to reach more surgeons.
"Closing this financing is a significant milestone for Meduloc as we move from product development and regulatory clearance into controlled commercialization," said Sarah Sachinis, president and chief executive officer.
Local backing: Three of the investors — Life Sciences Greenhouse Investments, Ben Franklin Technology Partners, and Broad Street Angels — reflect support from the Greater Philadelphia and wider Pennsylvania life sciences community. Ethier, a former Major League Baseball All-Star, framed his interest through an athlete's lens.
"Meduloc's approach stood out to me because of its potential to provide surgeons with an innovative treatment option and help patients return to the activities that matter to them," Ethier said.
What's next? Meduloc expects to begin its controlled alpha launch in early August 2026, working with a select group of orthopedic surgeons and institutions. The goal is to build clinical experience across multiple fracture applications and gather feedback to support later expansion.
The signal: A modest round anchored by regional backers shows how state-supported capital and local angels can carry a medical device startup through the delicate move from FDA clearance to market. For Meduloc, the money buys time to prove its platform in real surgical settings before scaling.
Image credit: US Army Africa
Read more: StreetInsider / PR Newswire
